Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.43 |
| ▸ | MLNR | O43193 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1798901 | 0.88 | HDAC1 (0.52) | LPAR1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1799338 | 0.87 | RAF1 (0.42) | — | |
| SCHEMBL1798511 | 0.84 | MLNR (0.43) | LPAR1MLNRHDAC1HDAC3HDAC2 | |
| SCHEMBL1799805 | 0.82 | HDAC1 (0.51) | LPAR1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL9823156 | 0.81 | HDAC1 (0.54) | LPAR1HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL1845666 | 0.80 | MEN1 (0.46) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL1797652 | 0.79 | PTGER1 (0.38) | LPAR1MLNRPTGER1PTGER4PTGER3 | |
| SCHEMBL1797650 | 0.79 | PTGER1 (0.38) | LPAR1MLNRPTGER1PTGER4PTGER3 | |
| SCHEMBL25048105 | 0.78 | HDAC1 (0.44) | HDAC1HDAC3HDAC2NCOR2HDAC6 | |
| SCHEMBL3695642 | 0.78 | HDAC1 (0.55) | LPAR1HDAC1HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | LPAR1 845/4885MLNR 355/4885HDAC1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.